Cervarix Filing Delay Will Not Impact The HPV Vaccine’s Market Potential – GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline is pushing back its Cervarix submission date four months until April.
You may also be interested in...
GSK Wagers On Cervarix In Head-To-Head Trial Against Gardasil
Trial will be the first to directly compare sustained immune response in women treated with the two cervical cancer vaccines.
GSK Wagers On Cervarix In Head-To-Head Trial Against Gardasil
Trial will be the first to directly compare sustained immune response in women treated with the two cervical cancer vaccines.
MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23
While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.